Top Markets
Coin of the day
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rang in Aktien #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Aktienkurs
$0.1502
Zuletzt synchronisiert: 2024-11-04
Marktkapitalisierung
$6.43M
Veränderung (1 Tag)
-5.45%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Renalytix Plc (RNLX)

Kategorie

Gewinn für Renalytix Plc (RNLX)
Gewinn im Sep 2024 TTM: $-28.67M
Laut den aktuellen Finanzberichten von Renalytix Plc betragen die aktuellen Gewinne des Unternehmens $-28.67M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-46.22M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-45.25M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Renalytix Plc von 2018 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-28.67M -14.29%
2024 $-33.45M -27.63%
2023 $-46.22M 2.14%
2022 $-45.25M 26.44%
2021 $-35.79M 237.30%
2020 $-10.61M 62.78%
2019 $-6.52M 1,459.33%
2018 $-418.00K 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$2.04B -7,225.67%
US
$222.34M -875.49%
AU
$295.53M -1,130.77%
US
$-259.89M 806.47%
US
- -
US